Paper Details

  1. Home
  2. Paper Details

Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.

Author: AgarwalKosh, AguilarHumberto, AsselahTarik, CalinasFilipe, ColomboMassimo, ElkhashabMagdy, HassaneinTarek, HezodeChristophe, HorsmansYves, KortJens, KowdleyKris V, KrishnanPreethi, LinChih-Wei, LiuRan, MantryParvez S, MarinhoRui Tato, MensaFederico J, NevensFrederik, NgTeresa I, WangStanley, ZadeikisNeddie, de LedinghenVictor

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Glecaprevir and pibrentasvir are new drugs used to treat hepatitis C. This study evaluated the safety and effectiveness of these drugs in patients with hepatitis C genotypes 2, 4, 5, or 6. The study found that these drugs were effective in treating hepatitis C and had a good safety profile.
Paper Details　
Original Abstract of the Article :
Hepatitis C virus (HCV) has high genotypic diversity and global distribution. Agents that are effective against all major HCV genotypes, with shorter treatment duration, are needed to reduce disease burden. Glecaprevir (an NS3/4A protease inhibitor) and pibrentasvir (an NS5A inhibitor) have a high b...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.cgh.2017.09.027

データ提供：米国国立医学図書館（NLM）

Glecaprevir/Pibrentasvir: A Promising Treatment for Hepatitis C

Hepatitis C virus (HCV) infection, a condition that can be as challenging to manage as navigating a winding desert path, is a significant public health concern. Researchers are constantly seeking more effective and shorter treatment options to combat this virus and reduce its impact on individuals and communities. This study investigated the efficacy of a combination therapy, glecaprevir/pibrentasvir, for treating HCV infection.

The researchers conducted clinical trials to evaluate the safety and efficacy of glecaprevir/pibrentasvir in patients with different HCV genotypes, specifically genotypes 2, 4, 5, and 6. They compared the effectiveness of treatment durations of 8 and 12 weeks, seeking to find the most efficient and effective approach. The study was akin to a desert explorer testing different routes, searching for the shortest and most efficient path to a successful outcome.

A Shorter, More Effective Treatment Option

The study found that glecaprevir/pibrentasvir was highly effective in treating HCV infection, regardless of the genotype. Moreover, they observed that an 8-week treatment duration was as effective as a 12-week duration for patients without cirrhosis. These findings are significant, as they suggest that glecaprevir/pibrentasvir could potentially shorten treatment duration and improve patient outcomes.

Navigating the Path to HCV Cure

This research offers a beacon of hope for individuals with HCV infection. The combination therapy of glecaprevir/pibrentasvir shows promise as a highly effective and potentially shorter treatment option. As always, it is essential to consult with a healthcare professional to discuss the best treatment options for your individual needs and to ensure that you receive appropriate care.

Dr.Camel's Conclusion

This study is a testament to the progress made in treating HCV infection. The development of more effective and shorter treatment options is a significant step forward in combating this virus and improving the lives of those affected. Like a desert explorer discovering a new and efficient route, we are continually seeking better ways to navigate the challenges of healthcare and find solutions that bring hope and healing.

Date :
  1. Date Completed 2019-11-06
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

28951228

DOI: Digital Object Identifier

10.1016/j.cgh.2017.09.027

Related Literature

Article Analysis
・Side Effects of glecaprevir and pibrentasvir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.